ELAN — Elanco Animal Health Incorporated

Elanco Animal Health Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $1,140 million, a 12% increase YoY; 9% organic constant currency growth.
• Full-Year Revenue: $4,715 million, representing 6% growth.
• Adjusted EBITDA: $189 million for Q4, up 7% YoY; full-year adjusted EBITDA of $901 million.
• Adjusted EPS: $0.13 for Q4, a 7% decrease YoY; full-year adjusted EPS at $0.94, up from $0.91 in 2024.
• Gross Margin: Adjusted gross margin for Q4 was 51.2%, a 30 basis point increase; full-year gross margin flat at 54.9%.
• Net Debt: Approximately $3,200 million with a net leverage ratio of 3.6 times.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance in US farm animal (up 17%) and US pet health (up 10%).
• Innovation Revenue: $892 million in 2025, with expectations to reach $1,150 million in 2026, driven by products like Credelio Quattro and ZENRELIA.
• Acquisition: Agreement to acquire AHV International, enhancing Elanco's portfolio in the dairy industry.
• Product Launches: Successful launches of key products, particularly in the parasiticide market, with Credelio Quattro gaining significant market share.
• Elanco Ascend Initiative: A productivity program aimed at improving operational efficiency and margin enhancement.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected organic constant currency growth of 4% to 6%, translating to revenue between $4,950 million and $5,020 million.
• Adjusted EBITDA Guidance: Forecasted at $955 to $985 million, reflecting 8% growth at the midpoint.
• Adjusted EPS Guidance: Expected between $1.00 and $1.06, representing a 10% increase at the midpoint.
• First Quarter Guidance: Anticipated organic constant currency growth of 4% to 6%, with revenue between $1,280 million and $1,305 million.

4. Bad News, Challenges, or Points of Concern

• Tax Rate Impact: Higher effective tax rate in 2025 impacted adjusted EPS.
• Competitive Pressures: Notable competition in the parasiticide market, particularly with generics and new entrants.
• Inflationary Pressures: Ongoing inflation affecting costs, with expectations of higher inventory costs impacting gross margins in the first half of 2026.
• Stocking Dynamics: While demand remains strong, concerns about potential stocking and destocking dynamics were raised.

5. Notable Q&A Insights

• ZENRELIA Market Share: Strong international performance with significant share gains in markets like Japan and Brazil, attributed to product efficacy.
• Pricing Strategy: Anticipated acceleration in pricing for 2026, moving from a 2% increase in 2025 to mid-single-digit growth, reflecting the value of new innovations.
• Corporate Accounts: Elanco's strategy to penetrate corporate accounts is showing positive results, with a focus on expanding product offerings.
• Innovation Pipeline: Confidence in the innovation pipeline remains high, with expectations for continued growth from key products.
• Cattle Market Outlook: Favorable cattle producer economics are expected to continue, supporting growth in the livestock segment.

Overall, Elanco demonstrated strong performance in 2025, with a positive outlook for 2026, although challenges such as competitive pressures and inflation remain pertinent.